DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Morepen Laboratories Limited (MOREPENLAB) share price today?

Morepen Laboratories Limited (MOREPENLAB) is trading at ₹123.5 on the NSE, down 1.67% on the day. Source: DocStoX.

What is the PE ratio of Morepen Laboratories Limited?

Morepen Laboratories Limited has a price-to-earnings (PE) ratio of 57.4 in the Healthcare sector.

What is the market capitalisation of Morepen Laboratories Limited?

Morepen Laboratories Limited has a market capitalisation of approximately ₹6,773 crore.

Is Morepen Laboratories Limited a profitable company?

Morepen Laboratories Limited generates a return on equity of 0.0% with a net profit margin of 5.3%. That is a modest return on shareholder capital.

What is the 52-week high and low of MOREPENLAB?

Morepen Laboratories Limited (MOREPENLAB) has traded between ₹33.05 and ₹150.7 over the past 52 weeks, against a current price of ₹123.5.

Does Morepen Laboratories Limited pay a dividend?

Yes. Morepen Laboratories Limited currently offers a dividend yield of 0.17%. Dividend payments depend on the board's declaration each year.

Morepen Laboratories Limited

₹123.50▼ -2.10 (-1.67%)

MOREPENLAB·NSE·Healthcare

Market Cap

6772.71 Cr

PE Ratio

57.44

Volume

25,84,217

Day High - Low

127.88 - 121.90

52W High-Low

150.70 - 33.05

₹123.50▼ -2.10 (-1.67%)

Market Cap6772.71 Cr

PE Ratio57.44

Volume25,84,217

Day High - Low127.88 - 121.90

52W High-Low150.70 - 33.05

Morepen Laboratories Limited (MOREPENLAB): company summary

The company's annual revenue fell 0.3% year-over-year, while its latest quarter revenue rose 34.1% compared to the same quarter a year earlier.

Morepen Laboratories Limited (MOREPENLAB) is a small-cap Healthcare company valued at ₹6,773 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Morepen Laboratories Limited last traded at ₹123.5, modestly down 1.67% on the day.
Recent developments: On 2026-10-14, the company informed the Exchange about actions taken or orders passed under XBRL, which may relate to regulatory or compliance matters affecting its operations.
Financial performance: The company's annual revenue fell 0.3% year-over-year, while its latest quarter revenue rose 34.1% compared to the same quarter a year earlier. Annual net profit dropped 19.6%, but the latest quarter net profit surged 412.7%, indicating a significant improvement in recent performance. The net profit margin narrowed 1.3 percentage points to 5.3%, and return on equity was 0.0%.
Valuation multiples: The stock trades at 57.4 times earnings, a premium to the Healthcare median of 32.0, 5.06 times book value. It yields 0.2%.
Things to watch: The company's annual net profit fell 19.6%, and the net profit margin narrowed 1.3 percentage points to 5.3%. The stock is 17.8% below its 52-week high, and return on equity was 0.0%.
Where it stands: The company's latest quarter showed strong growth in both revenue and net profit, but annual figures reflect a decline in net profit. The stock is 17.8% below its 52-week high, and return on equity was 0.0%.

Summarised by DocStoX's model on 2026-10-17 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

3.6/10

Poor

Fair Value

ROE

0.00%

Weak

P/E

57.44x

Expensive

Debt / Equity

0.17

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹121.90

₹127.88

52W₹33.05

₹150.70

DocStoX take

Supported by momentum (7.5) and risk (7.2), but held back by valuation (0.0). Momentum looks strong at 7.5, but that is offset by valuation at 0.0 and growth at 2.0 and quality at 2.6. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

3.6

/10

Poor

Quality

Weak

ROE 0.0%

Valuation

Expensive

P/E 57.4×

Growth

Flat

Revenue +8.7% 5Y CAGR

Risk

Moderate

D/E 0.17

Momentum

Strong

77% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹124

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹6,773 Cr

52W High / Low

₹151 / ₹33

Dividend Yield

0.17%

Promoter Holding

35.65%

EPS (TTM)

₹2.15

Book Value

₹22.75

Key highlights

Low leverage — D/E 0.17
Profitable in all of the last 5 years
Profit shrinking 0% a year
Valuation is weak (0.0/10)

2 Positives3 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Morepen Laboratories Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Morepen Laboratories Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Morepen Laboratories Limited with peers

Morepen Laboratories Limited vs Sun Pharmaceutical Industries Limited Morepen Laboratories Limited vs Divi's Laboratories Limited Morepen Laboratories Limited vs Torrent Pharmaceuticals Limited Morepen Laboratories Limited vs Apollo Hospitals Enterprise Limited Morepen Laboratories Limited vs Zydus Lifesciences Limited Morepen Laboratories Limited vs Laurus Labs Limited

Related tools & concepts

Value Morepen Laboratories Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

MOREPENLAB newsLatest coverage & filings Open screenerFilter the whole market